Orphenadrine Citrate

ORPHENADRINE CITRATE- orphenadrine citrate tablet, extended release
Aidarex Pharmaceuticals LLC


Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate is (±)-N,N -Dimethyl-2-[(o -methyl-α-phenylbenzyl)oxy]ethylamine citrate (1:1) having molecular formula C18 H23 NO•C6 H8 O7 and molecular weight of 461.51. It has the following structural formula:

Orphenadrine Citrate Chemical Structure
(click image for full-size original)

Each tablet for oral administration contains 100 mg orphenadrine citrate.

Each Orphenadrine citrate extended-release tablet contains the following inactive ingredients: hydroxypropyl methylcellulose, lactose monohydrate and magnesium stearate.


The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense muscles in man. Orphenadrine citrate also possesses anti-cholinergic actions.


Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.


Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis.

Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.


Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.


Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.

Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, cardiac arrhythmias.

Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.


Pregnancy Category C

Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.


Adverse reactions of orphenadrine are mainly due to the mild anti-cholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.


Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.


Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.



Two tablets per day; one in the morning and one in the evening.


Orphenadrine citrate extended-release tablets 100 mg are round, white tablets, debossed GG 931 on one side and plain on the reverse side and are supplied as:

NDC 33261-088-07 in bottles of 7 tablets
NDC 33261-088-14 in bottles of 7 tablets
NDC 33261-088-20 in bottles of 7 tablets
NDC 33261-088-28 in bottles of 7 tablets
NDC 33261-088-30 in bottles of 7 tablets
NDC 33261-088-60 in bottles of 7 tablets
NDC 33261-088-84 in bottles of 7 tablets
NDC 33261-088-90 in bottles of 7 tablets
NDC 33261-088-120in bottles of 7 tablets

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container.




Manufactured by
Sandoz Inc.
Princeton, NJ 08540

for GAVIS Pharmaceuticals, LLC
400 Campus Drive
Somerset, NJ 08873

Repackaged By:
Aidarex Pharmaceuticals, LLC.
Corona, CA 92880

100 mg Label

Image Label
(click image for full-size original)
orphenadrine citrate tablet, extended release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:33261-088(NDC:43386-480)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 10mm
Flavor Imprint Code GG931
# Item Code Package Description Multilevel Packaging
1 NDC:33261-088-02 120 TABLET, EXTENDED RELEASE (120 TABLET) in 1 BOTTLE None
2 NDC:33261-088-10 10 TABLET, EXTENDED RELEASE (10 TABLET) in 1 BOTTLE None
3 NDC:33261-088-14 14 TABLET, EXTENDED RELEASE (14 TABLET) in 1 BOTTLE None
4 NDC:33261-088-20 20 TABLET, EXTENDED RELEASE (20 TABLET) in 1 BOTTLE None
5 NDC:33261-088-28 28 TABLET, EXTENDED RELEASE (28 TABLET) in 1 BOTTLE None
6 NDC:33261-088-30 30 TABLET, EXTENDED RELEASE (30 TABLET) in 1 BOTTLE None
7 NDC:33261-088-60 60 TABLET, EXTENDED RELEASE (60 TABLET) in 1 BOTTLE None
8 NDC:33261-088-84 84 TABLET, EXTENDED RELEASE (84 TABLET) in 1 BOTTLE None
9 NDC:33261-088-90 90 TABLET, EXTENDED RELEASE (90 TABLET) in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040284 06/19/1998
Labeler — Aidarex Pharmaceuticals LLC (801503249)

Revised: 10/2012 Aidarex Pharmaceuticals LLC

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.